Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region [PDF]
Clinical and Molecular Hepatology, 2023 Even though the combined use of ultrasound (US) and alpha-fetoprotein (AFP) is recommended for the surveillance of hepatocellular carcinoma (HCC), the utilization of AFP has its challenges, including accuracy dependent on its cut-off levels, degree of ...
Do Young Kim +16 more
doaj +1 more source
Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients
BMC Cancer, 2021 Background Few biomarkers can predict the efficiency of PD-1 blockade in patients with hepatocellular carcinoma (HCC). This study aimed to investigate the prognostic role of AFP and PIVKA-II in HCC patients receiving anti-PD-1 immunotherapy.
Xuqi Sun +8 more
doaj +1 more source
Journal of the Formosan Medical Association, 2022 Background: The risk of hepatocellular carcinoma (HCC) is reduced but not eliminated after nucleos(t)ide analogue (NA) therapy in chronic hepatitis B (CHB).
Tung-Hung Su +9 more
doaj +1 more source
Pharmacokinetics and efficacy of oral versus intravenous mixed-micellar phylloquinone (vitamin K-1) in severe acute liver disease [PDF]
, 2005 Background/Aims: In patients with severe acute liver dysfunction, i.v. phylloquinone (vitamin K-1) may be given to exclude vitamin K deficiency, rather than impaired hepatic synthesis of coagulation factors alone, as the cause of the coagulopathy ...
Pereira, SP +13 more
core +1 more source
The potential of PIVKA-II as a treatment response biomarker in hepatocellular carcinoma: a prospective United Kingdom cohort study. [PDF]
, 2021 Prothrombin induced by vitamin K absence II (PIVKA-II) has recently been validated internationally as a diagnostic biomarker for hepatocellular carcinoma (HCC), as part of the GALAD model. However, its role as a treatment response biomarker has been less
Curbishley, Stuart +12 more
core +1 more source
Differential Associations of PIVKA-II with Epithelial and Mesenchymal Features in HCC and PDAC. [PDF]
Int J Mol SciHepatocellular carcinoma (HCC) and pancreatic ductal adenocarcinoma (PDAC) are aggressive malignancies characterized by a poor prognosis and resistance to conventional therapies.
Farina A +5 more
europepmc +2 more sources
Immunohistochemical studies of PIVKA-II in hepatocellular carcinoma by indirect immunofluorescence [PDF]
, 1995 Tissue PIVKA-II was examined in 32 hepatocellular carcinomas and 2 metastatic liver tumors using indirect immunofluorescence, and the results were compared with the size, histological grading and serum PIVKA-II level.
Ito, Toshio +4 more
core +1 more source
Kanzo, 2000 腫瘍径3cm以下の小肝細胞癌82症例 (針生検例44例, 外科的切除例38例) に対し高感度PIVKA-II測定の意義について検討した. PIVKA-II陽性率は腫瘍径3.0cm以下で34%, 2.0cm以下で21%であった.
KAMADA, Koji +15 more
openaire +3 more sources
Estudio del PIVKA-II y de otros marcadores angiogénicos y metastásicos en el trasplante hepático por hepatocarcinoma [PDF]
, 2022 El hepatocarcinoma (CHC) representa entre el 75-85% del total de neoplasias ocurrentes en el hígado. El trasplante ortotópico de hígado (TOH) es la mejor opción de tratamiento, ya que podría curar simultáneamente el tumor y la cirrosis subyacente.
Villalba López, Francisco
core
Positioning of novel tumor marker NX-PVKA-R in the diagnosis of hepatocellular carcinoma in comparison with PIVKA-II [PDF]
, 2013 Background/Aims:To compare the use of protein induced by vitamin K absence or antagonist II( PIVKA-II) measured conventionally with the ratio between PIVKA-II measured using P-11 and P-16 antibodies(NX-PVKA) and PIVKA-II measured conventionally (NX-PVKA ...
Suzuki, Kazutomo +5 more
core +1 more source